In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations. The findings will be published by the [...]

Antisense Therapeutics Ltd. (ASX: ANP) is pleased to report further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes. Along with [...]

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer. The long-term study results were presented at the 2009 American Society of Clinical Oncology annual meeting in Orlando, FL.

Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.

Current research suggests that lowering cholesterol may block the growth of prostate tumors.
The related report by Solomon et al, “Ezetimibe Is an Inhibitor of Tumor Angiogenesis,” appears in the March 2009 issue of The American Journal of Pathology .